Kenvue (KVUE) Stock Analysis & Winston Score
Kenvue is a consumer health company that makes everyday products people buy at pharmacies and grocery stores. Its brands include Tylenol, Neutrogena, Listerine, Band-Aid, and Aveeno — names most households already recognize. The company was spun off from Johnson & Johnson in 2023, making it one of the largest standalone consumer health companies in the world. Kenvue earns money by selling its products directly to retailers, pharmacies, and e-commerce platforms, which then sell to everyday consumers. It operates globally, with strong sales across North America, Europe, and Asia-Pacific, and generates over $15 billion in annual revenue. Its main competitive advantage is brand recognition — consumers tend to reach for familiar names like Tylenol or Band-Aid out of habit. The key risk is that retailers are pushing their own cheaper store-brand alternatives, which could pressure Kenvue's pricing power and market share over time.
Winston Score: 57/100 — Good
A decent business — some strong pillars, some weaker.
- Quality: Good (17/30)
- Growth: Strong (15/20)
- Cash Flow: Strong (8/10)
- Stability: Good (6/10)
- Valuation: Strong (7/10)
- Ownership: Weak (1/15)
Key Facts
Price: $18.98
Market Cap: $36.4B
Sector: Consumer Defensive
Industry: Household & Personal Products
Exchange: New York Stock Exchange


